Published in Osteoporos Int on January 01, 1998
Bone strength measured by peripheral quantitative computed tomography and the risk of nonvertebral fractures: the osteoporotic fractures in men (MrOS) study. J Bone Miner Res (2011) 1.16
Bone density in cerebral palsy. Phys Med Rehabil Clin N Am (2009) 1.12
Obesity alters cortical and trabecular bone density and geometry in women. Osteoporos Int (2010) 1.07
Choice of study phenotype in osteoporosis genetic research. J Bone Miner Metab (2009) 0.82
Can geometry-based parameters from pQCT and material parameters from quantitative ultrasound (QUS) improve the prediction of radial bone strength over that by bone mass (DXA)? Osteoporos Int (2004) 0.81
Non-invasive Assessment of Lower Limb Geometry and Strength Using Hip Structural Analysis and Peripheral Quantitative Computed Tomography: A Population-Based Comparison. Calcif Tissue Int (2015) 0.79
Correlation of cervical endplate strength with CT measured subchondral bone density. Eur Spine J (2007) 0.78
A Trimodality Comparison of Volumetric Bone Imaging Technologies. Part III: SD, SEE, LSC Association With Fragility Fractures. J Clin Densitom (2014) 0.75
Cervical vertebral trabecular bone mineral density in Great Danes with and without osseous-associated cervical spondylomyelopathy. J Vet Intern Med (2014) 0.75
A multifactorial intervention to reduce the risk of falling among elderly people living in the community. N Engl J Med (1994) 11.54
The genome of the social amoeba Dictyostelium discoideum. Nature (2005) 9.18
Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int (1998) 7.14
Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int (2014) 5.17
The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial. Kidney Int (2011) 4.27
Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment. Lancet (1976) 4.24
Insulin-like growth factor-I in men with idiopathic osteoporosis. J Clin Endocrinol Metab (1997) 3.00
An assessment tool for predicting fracture risk in postmenopausal women. Osteoporos Int (2001) 2.94
Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet (1997) 2.78
Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int (1999) 2.70
Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res (2001) 2.65
Calcium potentiates the effect of estrogen and calcitonin on bone mass: review and analysis. Am J Clin Nutr (1998) 2.37
Prevention of spinal osteoporosis in oophorectomised women. Lancet (1980) 2.34
Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int (2006) 2.34
Two types of astrocytes in cultures of developing rat white matter: differences in morphology, surface gangliosides, and growth characteristics. J Neurosci (1983) 2.18
Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab (2000) 2.14
Anabolic actions of parathyroid hormone on bone. Endocr Rev (1993) 2.13
Cancer rates after the Three Mile Island nuclear accident and proximity of residence to the plant. Am J Public Health (1991) 2.11
Cancer near the Three Mile Island nuclear plant: radiation emissions. Am J Epidemiol (1990) 2.04
Resistance to bone resorbing effects of PTH in black women. J Bone Miner Res (1997) 1.98
Fracture history and bone loss in patients with MS. Neurology (1998) 1.97
Pathogenesis of osteoporosis. Lancet (1993) 1.93
The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design. Osteoporos Int (2009) 1.85
Importance of precision in bone density measurements. J Clin Densitom (2001) 1.82
The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol (1984) 1.80
Oestrogen replacement therapy for prevention of osteoporosis after oophorectomy. Br Med J (1973) 1.79
Cytokine profile in patients with multiple sclerosis following vitamin D supplementation. J Neuroimmunol (2003) 1.74
Phanerozoic stromatolites: noncompetitive ecologic restriction by grazing and burrowing animals. Science (1970) 1.64
Fragility fractures of the hip and femur: incidence and patient characteristics. Osteoporos Int (2009) 1.63
The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int (2002) 1.61
Dietary risk factors for the incidence and recurrence of colorectal adenomatous polyps. A case-control study. Ann Intern Med (1993) 1.58
Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int (2004) 1.57
High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology (1994) 1.54
On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism. J Clin Endocrinol Metab (1999) 1.53
Progeston therapy for menstrually related aphthae. Int J Oral Surg (1978) 1.52
The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone structure. J Clin Endocrinol Metab (1990) 1.51
Comparative effects of oestrogen and a progestogen on bone loss in postmenopausal women. Clin Sci Mol Med (1978) 1.50
Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate. Osteoporos Int (2008) 1.44
Exogenous calciferol (vitamin D) and vitamin D endocrine status among elderly nursing home residents in the New York City area. J Am Geriatr Soc (1993) 1.42
Constant mineralization density distribution in cancellous human bone. Bone (2003) 1.41
Therapeutic controversy: Estrogen replacement in menopause. J Clin Endocrinol Metab (1996) 1.41
Bone response to termination of oestrogen treatment. Lancet (1978) 1.38
The redistribution of body sodium in women on long-term oestrogen therapy. Clin Sci Mol Med (1974) 1.38
Interaction of calcium nutrition and physical activity on bone mass in young women. J Bone Miner Res (1988) 1.37
Prevention of bone mineral loss in postmenopausal women by norethisterone. Obstet Gynecol (1985) 1.37
Histomorphometric assessment of bone mass, structure, and remodeling: a comparison between healthy black and white premenopausal women. J Bone Miner Res (1997) 1.36
Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res (2001) 1.33
Home-based multicomponent rehabilitation program for older persons after hip fracture: a randomized trial. Arch Phys Med Rehabil (1999) 1.27
Milk and bones. BMJ (1994) 1.27
Elementary schoolteachers' understanding of diabetes. Diabetes Educ (1987) 1.27
The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporos Int (2014) 1.27
Bone mass and vitamin D deficiency in adults with advanced cystic fibrosis lung disease. Am J Respir Crit Care Med (1998) 1.25
Prospective double-blind trial of synthetic steroid (Org OD 14) for preventing postmenopausal osteoporosis. Br Med J (1980) 1.24
Maintenance of cancellous bone connectivity in primary hyperparathyroidism: trabecular strut analysis. J Bone Miner Res (1992) 1.23
Prevention of osteoporosis. Clin Orthop Relat Res (1987) 1.22
Serum vitamin D2 and vitamin D3 metabolite concentrations and absorption of vitamin D2 in elderly subjects. J Clin Endocrinol Metab (1986) 1.18
Osteoporosis after oophorectomy for non-malignant disease in premenopausal women. Br Med J (1973) 1.17
Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med (2000) 1.17
Effect of Na, metabolic inhibitors and ATP on Ca movements in L cells. J Physiol (1971) 1.16
Effects of tamoxifen on spinal bone density in women with breast cancer. J Natl Cancer Inst (1989) 1.15
Primary radiation therapy for juvenile nasopharyngeal angiofibroma. Laryngoscope (1984) 1.13
Bone mass and body composition in normal women. J Bone Miner Res (1992) 1.13
The anabolic effects of parathyroid hormone. Osteoporos Int (2002) 1.13
Bone structure in postmenopausal hyperparathyroid, osteoporotic, and normal women. J Bone Miner Res (1995) 1.12
Estrogen protection against bone resorbing effects of parathyroid hormone infusion. Assessment by use of biochemical markers. Ann Intern Med (1993) 1.11
Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone-(1-34): kinetics and biochemical response in estrogenized osteoporotic patients. J Clin Endocrinol Metab (1993) 1.10
Temporal expression of the anabolic action of PTH in cancellous bone of ovariectomized rats. J Bone Miner Res (1996) 1.09
A comparison of two laser-based methods for determination of burn scar perfusion: laser Doppler versus laser speckle imaging. Burns (2005) 1.08
Reduced bone mass and fat-free mass in women with multiple sclerosis: effects of ambulatory status and glucocorticoid Use. Calcif Tissue Int (1997) 1.08
Fluoride and bone--quantity versus quality. N Engl J Med (1990) 1.08
Screening for hyperglycaemia in pregnancy: a rapid update for the National Screening Committee. Health Technol Assess (2010) 1.06
Migration of axonal protein: absence of a protein concentration gradient and effect of inhibition of protein synthesis. Exp Brain Res (1967) 1.05
Continuous parathyroid hormone and estrogen administration increases vertebral cancellous bone volume and cortical width in the estrogen-deficient rat. J Bone Miner Res (2001) 1.05
A new manual method for assessing two-dimensional cancellous bone structure: comparison between iliac crest and lumbar vertebra. J Bone Miner Res (1991) 1.03
Selective estrogen receptor modulators: clinical spectrum. Endocr Rev (1999) 1.03
Systematic home-based physical and functional therapy for older persons after hip fracture. Arch Phys Med Rehabil (1997) 1.01
Identifying the last supper: utility of the DNA barcode library for bloodmeal identification in ticks. Mol Ecol Resour (2012) 1.01
Estrogens, bone loss and preservation. Osteoporos Int (1990) 1.01
Bone-resorbing activity in the sera of patients with rheumatoid arthritis. Clin Sci Mol Med (1976) 1.00
Disease-specific perception of fracture risk and incident fracture rates: GLOW cohort study. Osteoporos Int (2013) 1.00
Anabolic action of parathyroid hormone on cortical and cancellous bone differs between axial and appendicular skeletal sites in mice. Bone (2003) 1.00
The systemic effect of intraarticular administration of corticosteroid on markers of bone formation and bone resorption in patients with rheumatoid arthritis. Arthritis Rheum (1996) 1.00
Is reactive gliosis a property of a distinct subpopulation of astrocytes? J Neurosci (1986) 0.99
Short-term continuous infusion of human parathyroid hormone 1-34 fragment is catabolic with decreased trabecular connectivity density accompanied by hypercalcemia in C57BL/J6 mice. J Endocrinol (2005) 0.98
Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J Clin Endocrinol Metab (1999) 0.98
Genetic and serotypic characterization of Sin Nombre-like viruses in Canadian Peromyscus maniculatus mice. Virus Res (2001) 0.97
Indices to quantify changes in intracranial and cerebral perfusion pressure by assessing agreement between hourly and semi-continuous recordings. Intensive Care Med (2004) 0.96
Radiological determination of changes in bone mineral content. Radiography (1978) 0.96